NIB finances pharmaceutical gene therapy manufacturing in Finland
The Nordic Investment Bank (NIB) and Finnish FinVector Oy, a Ferring Ventures company, have signed a twelve-year EUR 45 million loan for the building of FinVector’s new viral-based gene therapy drug production unit in Kuopio, Finland. The investment is part of FinVector’s long-term commitment to the development and manufacturing of gene therapy-based medicines in Finland. When the unit under construction starts its operations, it will primarily focus on the production of a new viral-based gene therapy drug for bladder cancer. FinVector’s goal is to continue to be a pioneer as a developer